Protagonist Therapeutics (PTGX) Long-Term Debt Issuances: 2019-2023
- Protagonist Therapeutics' Long-Term Debt Issuances rose 66.99% to $24.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $64.1 million, marking a year-over-year increase of 0.55%. This contributed to the annual value of $24.3 million for FY2023, which is 66.99% up from last year.
- According to the latest figures from Q1 2023, Protagonist Therapeutics' Long-Term Debt Issuances is $24.3 million, which was up 66.99% from $14.6 million recorded in Q1 2022.
- In the past 5 years, Protagonist Therapeutics' Long-Term Debt Issuances registered a high of $24.3 million during Q1 2023, and its lowest value of $6.4 million during Q3 2020.
- Its 2-year average for Long-Term Debt Issuances is $19.4 million, with a median of $19.4 million in 2022.
- Per our database at Business Quant, Protagonist Therapeutics' Long-Term Debt Issuances tumbled by 73.34% in 2020 and then spiked by 66.99% in 2023.
- Over the past 4 years, Protagonist Therapeutics' Long-Term Debt Issuances (Quarterly) stood at $23.9 million in 2019, then plummeted by 73.34% to $18.8 million in 2020, then reached $14.6 million in 2022, then skyrocketed by 66.99% to $24.3 million in 2023.
- Its Long-Term Debt Issuances stands at $24.3 million for Q1 2023, versus $14.6 million for Q1 2022 and $18.8 million for Q4 2020.
